Migraine News and Research

Latest Migraine News and Research

Women Veterans had a lower prevalence of pain than male counterparts returning from the conflicts: Study

In the first study to look at sex-specific pain prevalence in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) Veterans, researchers from the VA Connecticut Healthcare System and the Yale University School of Medicine found women Veterans had a lower prevalence of pain than male counterparts returning from the conflicts. Approximately 60% of OEF/OIF Veterans were assessed with pain during the study period.

21 Oct 2009

New cutting edge nerve procedure relieves migraine permanently

The Plastic Surgery Center today announced that a 57-year-old Plainfield man reports he is free of constant headache pain after undergoing a new cutting edge nerve procedure to permanently eliminate pain caused by migraines. The procedure was performed by plastic and reconstructive surgeon Dr. Matthew Kaufman, of the Plastic Surgery Center in New Jersey on August 4, 2009.

21 Oct 2009

Update from Endo Pharmaceuticals regarding its New Drug Application for FORTESTA

Endo Pharmaceuticals today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for FORTESTA(TM) (testosterone) 2% Gel for men diagnosed with low testosterone (Low T), also known as hypogonadism.

19 Oct 2009

XenoPort commences Phase 2b arbaclofen placarbil clinical trial for treating gastroesophageal reflux disease

XenoPort, Inc. announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite treatment with a proton pump inhibitor (PPI). The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of AP as adjunctive therapy to PPIs.

19 Oct 2009

Migraine can stimulate alcohol-induced headache

Migraine sufferers, beware. You may be more prone to an alcohol-induced headache after a night of drinking, according to researchers from the Jefferson Headache Center.

19 Oct 2009

Managing Myeloma launches educational activities for multidisciplinary professionals

Managing Myeloma (www.ManagingMyeloma.com), an accredited educational initiative for multidisciplinary professionals, announces the launch of a series of regional continuing education activities to be held through October and November in five western states.

15 Oct 2009

Managing Myeloma website offers scholarship for attending the December 2009 American Society of Hematology Annual Meeting

Managing Myeloma (www.ManagingMyeloma.com), an accredited multi-supported educational website for multidisciplinary professionals, announces the opportunity for fellows in oncology to win a scholarship to attend the December 2009 American Society of Hematology Annual Meeting in New Orleans, Louisiana. The scholarship includes registration fees, airfare, hotel accommodations, and a per diem for meals.

15 Oct 2009

Meda Pharmaceuticals introduces Onsolis for treating breakthrough cancer pain

Meda Pharmaceuticals Inc. today announced the launch of Onsolis(TM)(fentanyl buccal soluble film) in the U.S. for the management of breakthrough pain (BTP) in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

13 Oct 2009

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

13 Oct 2009

New sports division established to address athletes' neurological problems

On the football field, the hockey rink or wrestling mat, an athletes' head can take a beating -- and a University of Michigan neurologist is leading the charge to help doctors who treat the brain better understand those sports injuries.

13 Oct 2009

Guidelines for treating amyotrophic lateral sclerosis identified

New guidelines from the American Academy of Neurology identify the most effective treatments for amyotrophic lateral sclerosis (ALS), often called Lou Gehrig's disease. The guidelines are published in the October 13, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology.

13 Oct 2009

BioDelivery Sciences' partner Meda to launch ONSOLIS for managing breakthrough pain

BioDelivery Sciences International, Inc. announced that its commercial partner Meda will launch the FDA-approved ONSOLIS (fentanyl buccal soluble film) next week for the management of breakthrough pain (BTP) in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

8 Oct 2009

APP Pharmaceuticals receives FDA approval to market Sumatriptan Succinate Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Sumatriptan Succinate Injection, USP, in two dosage strengths.

8 Oct 2009

GSK reports positive Phase II results from trial evaluating GSK1838262 for post-herpetic neuralgia

GlaxoSmithKline and XenoPort, Inc. today announced top-line results from a Phase II clinical trial evaluating GSK1838262/XP13512 (gabapentin enacarbil) in adult patients with neuropathic pain associated with post-herpetic neuralgia (PHN) who have had a history of inadequate response to gabapentin doses of 1800 mg/day or higher.

5 Oct 2009

sNDA for Clonicel submitted to the FDA

Addrenex Pharmaceuticals and Sciele Pharma, Inc., a Shionogi company today announced that Addrenex has submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) for Clonicel (modified-release clonidine) to treat attention deficit hyperactivity disorder (ADHD).

2 Oct 2009

Alexza enters into agreement with institutional investors to raise $19.7 million

Alexza Pharmaceuticals, Inc. announced today that it has entered into a definitive agreement with various institutional investors to raise $19.7 million in a private placement of its common stock.

1 Oct 2009

Transient ischemic attack can trigger stroke

One out of every eight strokes is preceded by a "warning stroke," which is a transient ischemic attack (TIA) or mild stroke, according to research published in the September 29, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.

29 Sep 2009

District court of Frankfurt, Germany rules in favour of Occlutech

Occlutech GmbH, the leading European developer of products for septal closure, today announced that the district court of Frankfurt, Germany reversed an earlier court injunction obtained by AGA Medical against Occlutech's sales and marketing activities relating to the newly launched Figulla Flex ranges of ASD and PFO occluders.

24 Sep 2009

Abbott, Coherex Medical sign multi-year distribution agreement

Salt Lake City-based Coherex Medical, Inc. today announced that it has entered into a multi-year distribution agreement with global health care company Abbott for the Coherex FlatStent™ EF PFO Closure System.

23 Sep 2009

Results from Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 announced

GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) today announced top-line results from a Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 (gabapentin enacarbil) for neuropathic pain associated with post-herpetic neuralgia (PHN) in adults.

17 Sep 2009

Migraine News and Research

Latest Migraine News and Research

Women Veterans had a lower prevalence of pain than male counterparts returning from the conflicts: Study

New cutting edge nerve procedure relieves migraine permanently

Update from Endo Pharmaceuticals regarding its New Drug Application for FORTESTA

XenoPort commences Phase 2b arbaclofen placarbil clinical trial for treating gastroesophageal reflux disease

Migraine can stimulate alcohol-induced headache

Managing Myeloma launches educational activities for multidisciplinary professionals

Managing Myeloma website offers scholarship for attending the December 2009 American Society of Hematology Annual Meeting

Meda Pharmaceuticals introduces Onsolis for treating breakthrough cancer pain

Johnson & Johnson announces financial results for the third quarter of 2009

New sports division established to address athletes' neurological problems

Guidelines for treating amyotrophic lateral sclerosis identified

BioDelivery Sciences' partner Meda to launch ONSOLIS for managing breakthrough pain

APP Pharmaceuticals receives FDA approval to market Sumatriptan Succinate Injection

GSK reports positive Phase II results from trial evaluating GSK1838262 for post-herpetic neuralgia

sNDA for Clonicel submitted to the FDA

Alexza enters into agreement with institutional investors to raise $19.7 million

Transient ischemic attack can trigger stroke

District court of Frankfurt, Germany rules in favour of Occlutech

Abbott, Coherex Medical sign multi-year distribution agreement

Results from Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 announced

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Migraine News and Research

Latest Migraine News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in